Carsten C. Skarke, M.D.

Selected Publications

Skarke C, Alamuddin N, Lawson JA, Cen L, Propert KJ, FitzGerald GA: Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. Clin Pharmacol Ther 91(6): 986-93, June 2012.

Skarke C, Kuczka K, Tausch L, Werz O, Rossmanith T, Barrett JS, Harder S, Holtmeier W, Schwarz JA: Increased bioavailability of 11‑keto-beta-boswellic acid following single oral dose frankincense extract administration after a standardized meal in healthy male volunteers: Modeling and simulation considerations for evaluating drug exposures. J Clin Pharmacol 52(10): 1592-1600, October 2012.

Skarke Carsten, FitzGerald Garret A: Training translators for smart drug discovery. Science Translational Medicine. American Association for the Advancement of Science, 2(26): 26cm12, April 2010.

Skarke C, Schuss P, Kirchhof A, Doehring A, Geißlinger G, Lötsch J: PyrosequencingTM of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics 8(12): 1643-1660, December 2007.

Skarke C, Reus M, Schmidt R, Grundei I, Schuss P, Geisslinger G, Lötsch J: The cyclooxygenase-2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clin Pharmacol Ther 80(6): 621-632, December 2006.

Skarke C, Geisslinger G, Lötsch J: Is morphine-3-glucuronide clinically important? Pain 116(3): 177-180, August 2005.

Skarke C, Langer M, Jarrar M, Schmidt H, Geisslinger G, Lötsch J: Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans. Anesthesiology 101(6): 1394-1399, December 2004.

Skarke C, Kirchhof A, Geisslinger G, Lötsch J: Comprehensive mu-opioid-receptor genotyping by pyrosequencing. Clin Chem 50(3): 640-644, March 2004.

Skarke C, Jarrar M, Erb K, Schmidt H, Geisslinger G, Lötsch J : Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 74(4): 303-311, October 2003.

Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, Lötsch J: Effects of ABCB1 (multi drug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 13(11): 651-660, November 2003.

Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73(1): 107-121, January 2003.

Skarke C, Schmidt H, Geisslinger G, Darimont J, Lötsch J: Pharmacokinetics of morphine are not altered in persons with Gilbert's syndrome. Brit J Clin Pharmacol 56(2): 228-231, August 2003.

Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G: The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12(1): 3-9, January 2002.

Lotsch J, Skarke C, Schmidt H, Liefhold J, Geisslinger G : Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. Clin Pharmacol Ther 72(2): 151-162, August 2002.

Lotsch J, Skarke C, Schmidt H, Grosch S, Geisslinger G: The transfer half-life of morphine-6-beta-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers Anesthesiology 95(6): 1329-1338, December 2001.